Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients

doi:10.3748/wjg.v28.i45.6380

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 45

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3259)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-7) series.

Item

Count

PDF

206

WORD

HTML

1785

Figures (1-1)

235

Tables (1-7)

236

Sum=2516

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

230

Download

513

Sum=743

Dec 7, 2022 (publication date) through May 3, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Dec 7, 2022; 28(45): 6380-6396
Published online Dec 7, 2022. doi: 10.3748/wjg.v28.i45.6380

Table 1 Baseline characteristics of 11385 genotype 1b-infected patients treated with interferon-free regimens

Parameter	GT1b patients, n = 11385
Sex, female/male, n (%)	6085 (53.4)/5300 (46.6)
Age in yr, mean ± SD; min-max	53 ± 14.8; 17-97
Females	54.8 ± 15.1; 18-92
Males	51 ± 14.3; 17-97
BMI, kg/m² mean ± SD; min-max	26.3 ± 4.5; 13.2-57.4
Comorbidities, n (%)
Any comorbidity	7280 (63.9)
Hypertension	4013 (35.2)
Diabetes	1447 (12.7)
Renal disease	470 (4.1)
Autoimmune diseases	251 (2.2)
Non-HCC tumors	237 (2.1)
Other	5330 (46.8)
Concomitant medications, n (%)	6842 (60.1)
Liver fibrosis n(%)
F0	237 (2.1)
F1	4440 (39)
F2	2135 (18.8)
F3	1587 (13.9)
F4	2768 (24.3)
No data	218 (1.9)
HCC history, n (%)	175 (1.5)
OLTx history, n (%)	122 (1.1)
HBV coinfection (HBsAg+), n (%)	106 (0.9)
HIV coinfection, n (%)	359 (3.1)
ALT IU/L, mean ± SD	75.8 ± 65.5
Bilirubin mg/dL, mean ± SD	0.8 ± 0.9
Albumin g/dL, mean ± SD	4.3 ± 3.2
Creatinine mg/dL, mean ± SD	0.9 ± 1.8
Hemoglobin g/dL, mean ± SD	14.4 ± 1.8
Platelets × 1000/μL, mean ± SD	195.3 ± 77.8
HCV RNA × 10⁶ IU/mL, mean ± SD	2.1 ± 4.7

ALT: Alanine transaminase; BMI: Body mass index; F: Fibrosis; GT: Genotype; HBsAg+: Hepatitis B surface antigen; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; IFN: Interferon; OLTx: Orthotopic liver transplantation; SD: Standard deviation.

Citation: Zarębska-Michaluk D, Brzdęk M, Jaroszewicz J, Tudrujek-Zdunek M, Lorenc B, Klapaczyński J, Mazur W, Kazek A, Sitko M, Berak H, Janocha-Litwin J, Dybowska D, Supronowicz Ł, Krygier R, Citko J, Piekarska A, Flisiak R. Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients. World J Gastroenterol 2022; 28(45): 6380-6396
URL: https://www.wjgnet.com/1007-9327/full/v28/i45/6380.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i45.6380